Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, Minar L, Melichar B, Hein A, Kieszko D, Pluta M, Spacek J, Bartos P, Wimberger P, Madry R, Markowska J, Streb J, Valha P, Hassan HIB, Pecen L, Galluzzi L, Fucikova J, Hrnciarova T, Hraska M, Bartunkova J, Spisek R. Cibula D, et al. Among authors: hrnciarova t. Gynecol Oncol. 2021 Sep;162(3):652-660. doi: 10.1016/j.ygyno.2021.07.003. Epub 2021 Jul 20. Gynecol Oncol. 2021. PMID: 34294416 Free article. Clinical Trial.
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L, Bartos P, Chovanec J, Valha P, Pluta M, Novotny Z, Spacek J, Melichar B, Kieszko D, Fucikova J, Hrnciarova T, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Rob L, et al. Among authors: hrnciarova t. J Immunother Cancer. 2022 Jan;10(1):e003190. doi: 10.1136/jitc-2021-003190. J Immunother Cancer. 2022. PMID: 34992091 Free PMC article. Clinical Trial.
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.
Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T, Sochorova K, Rozkova D, Sojka L, Dundr P, Laco J, Brtnicky T, Praznovec I, Halaska MJ, Rob L, Ryska A, Coosemans A, Vergote I, Cibula D, Bartunkova J, Galon J, Galluzzi L, Spisek R. Fucikova J, et al. Among authors: hrnciarova t. Clin Cancer Res. 2022 Jul 15;28(14):3053-3065. doi: 10.1158/1078-0432.CCR-21-4413. Clin Cancer Res. 2022. PMID: 35536547 Clinical Trial.
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines.
Hensler M, Rakova J, Kasikova L, Lanickova T, Pasulka J, Holicek P, Hraska M, Hrnciarova T, Kadlecova P, Schoenenberger A, Sochorova K, Rozkova D, Sojka L, Drozenova J, Laco J, Horvath R, Podrazil M, Hongyan G, Brtnicky T, Halaska MJ, Rob L, Ryska A, Coosemans A, Vergote I, Garg AD, Cibula D, Bartunkova J, Spisek R, Fucikova J. Hensler M, et al. Among authors: hrnciarova t. Oncoimmunology. 2022 Jul 22;11(1):2101596. doi: 10.1080/2162402X.2022.2101596. eCollection 2022. Oncoimmunology. 2022. PMID: 35898703 Free PMC article.
Lipidomic profiling of human serum enables detection of pancreatic cancer.
Wolrab D, Jirásko R, Cífková E, Höring M, Mei D, Chocholoušková M, Peterka O, Idkowiak J, Hrnčiarová T, Kuchař L, Ahrends R, Brumarová R, Friedecký D, Vivo-Truyols G, Škrha P, Škrha J, Kučera R, Melichar B, Liebisch G, Burkhardt R, Wenk MR, Cazenave-Gassiot A, Karásek P, Novotný I, Greplová K, Hrstka R, Holčapek M. Wolrab D, et al. Among authors: hrnciarova t. Nat Commun. 2022 Jan 10;13(1):124. doi: 10.1038/s41467-021-27765-9. Nat Commun. 2022. PMID: 35013261 Free PMC article.
Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.
Horakova D, Rockova P, Jircikova J, Dolezal T, Vachova M, Hradilek P, Valis M, Sucha J, Martinkova A, Ampapa R, Grunermelova M, Stetkarova I, Stourac P, Mares J, Dufek M, Kmetova E, Adamkova J, Hrnciarova T. Horakova D, et al. Among authors: hrnciarova t. Mult Scler Relat Disord. 2019 Oct;35:196-202. doi: 10.1016/j.msard.2019.08.003. Epub 2019 Aug 3. Mult Scler Relat Disord. 2019. PMID: 31400559
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T, Drahota J, Spelman T, Hillert J, Lycke J, Kubala Havrdova E, Recmanova E, Adamkova J, Mares J, Libertinova J, Pavelek Z, Hradilek P, Ampapa R, Stetkarova I, Peterka M, Martinkova A, Stourac P, Grunermelova M, Vachova M, Dufek M, Horakova D. Hrnciarova T, et al. Mult Scler Relat Disord. 2023 Aug;76:104803. doi: 10.1016/j.msard.2023.104803. Epub 2023 Jun 12. Mult Scler Relat Disord. 2023. PMID: 37329786
13 results